FDA Approves Tivicay PD for HIV Treatment in Neonates

The U.S. Food and Drug Administration (FDA) has approved Tivicay PD oral suspension for treating HIV in newborns from birth. This significant regulatory decision, supported by pharmacokinetic data from the IMPAACT 2023 study, expands treatment options for a vulnerable patient population.